

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
**(Case No 05-980-F; (EX03-067C-US))**

<b>In the Application of:</b>	)	
	)	
<b>Francis-Lang <i>et al.</i></b>	)	
	)	<b>Examiner: Berttoglio, Valarie</b>
<b>Serial No.: 10/528,021</b>	)	
	)	<b>Group Art Unit: 1632</b>
<b>Filing Date: July 29, 2005</b>	)	
	)	<b>Confirmation No. 1018</b>
<b>For: PAKs as Modifiers of the CHK</b>	)	
<b>Pathway and Methods of Use</b>	)	

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the restriction requirement mailed on August 8, 2007, in the above-mentioned application. Applicants submit herewith a petition for a five month extension of time and the appropriate fee. It is believed that no further fee is due in connection with this filing. However, if a fee is due the Commissioner is authorized to charge our deposit account 13-2490.

With respect to the restriction requirement, Applicants hereby elect with traverse Group III, drawn to an in vitro method of identifying a candidate CHK pathway modulating agent comprising providing an assay system wherein the assay system is a cell proliferation assay system, for prosecution on the merits. The claims readable thereon are claims 1-4, 6, and 16-17.

If the Examiner has any questions regarding this response, she is invited to call the undersigned attorney.

Respectfully submitted,

Dated: February 8, 2008

/Anita J. Terpstra/  
Anita J. Terpstra, Ph.D.  
Registration No. 47,132

McDonnell, Boehnen,  
Hulbert & Berghoff LLP  
300 S. Wacker Drive  
Chicago, IL 60606  
(312) 913-0001